Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group by Thabane, Lehana et al.
COMMENTARY Open Access
Canadian-led capacity-building in biostatistics
and methodology in cardiovascular and diabetes
trials: the CANNeCTIN Biostatistics and
Methodological Innovation Working Group
Lehana Thabane
1,2,3,4*, George Wells
5, Richard Cook
6, Robert Platt
7, Janice Pogue
4, Eleanor Pullenayegum
1,2,3,
David Matthews
6, Tara McCready
4, Philip J Devereaux
1,4, John A Cairns
8, Salim Yusuf
1,4,9,
the CANadian Network and Centre for Trials Internationally (CANNeCTIN) Investigators
Abstract
The Biostatistics and Methodological Innovation Working (BMIW) Group is one of several working groups within
the CANadian Network and Centre for Trials INternationally (CANNeCTIN). This programme received funding from
the Canadian Institutes of Health Research and the Canada Foundation for Innovation beginning in 2008, to
enhance the infrastructure and build capacity for large Canadian-led clinical trials in cardiovascular diseases (CVD)
and diabetes mellitus (DM). The overall aims of the BMIW Group’s programme within CANNeCTIN, are to advance
biostatistical and methodological research, and to build biostatistical capacity in CVD and DM. Our program of
research and training includes: monthly videoconferences on topical biostatistical and methodological issues in
CVD/DM clinical studies; providing presentations on methods issues at the annual CANNeCTIN meetings;
collaborating with clinician investigators on their studies; training young statisticians in biostatistics and methods in
CVD/DM trials and organizing annual symposiums on topical methodological issues. We are focused on the
development of new biostatistical methods and the recruitment and training of highly qualified personnel - who
will become leaders in the design and analysis of CVD/DM trials. The ultimate goal is to enhance global health by
contributing to efforts to reduce the burden of CVD and DM.
Background
Jointly funded beginning in 2008 by the Canadian Insti-
tutes of Health Research (CIHR) and the Canada Foun-
dation for Innovation (CFI), the CANadian Network and
Centre for Trials INternationally (CANNeCTIN) was
among five successful applications under the CIHR-CFI
strategic initiative to support clinical research programs,
teams and network infra-structure that focused on high-
impact, clinically relevant problems [1]. CIHR is the
Canadian equivalent of the US National Institutes of
Health. It was established by the Canadian federal gov-
ernment in 2000, as the successor to the Medical
Research Council and currently supports more than
13,000 health researchers and trainees in universities,
teaching hospitals and other health organizations and
research centres across the country. CFI is an indepen-
dent corporation created in 1997 by the Government of
Canada to fund research infrastructure. The CFI’sm a n -
date is to strengthen the capacity of Canadian universi-
ties, colleges, research hospitals, and non-profit research
institutions to carry out world-class research and tech-
nology development that benefits Canadians.
The focus for CANNeCTIN is to enhance the infrastruc-
ture and to build capacity for clinical trials in cardiovascu-
lar diseases (CVD) and diabetes mellitus (DM), especially
those with a focus on neglected conditions, outcomes and
interventions. There is an explicit goal to build capacity by
developing young trialists who could emerge to be the lea-
ders of large trials and expanding biostatistical expertise as
it relates to clinical trials. Led by Salim Yusuf (Hamilton
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Cairns (University of British Columbia), and coordinated
by the Population Health Research Institute (PHRI)
(Hamilton, Ontario), CANNECTIN has engaged more
than 100 researchers from 19 universities including all of
Canada’s 17 medical schools. This network is linked to an
international network of over 1500 affiliated hospitals and
clinics from 80 countries [1] and is committed to develop-
ing links with investigators in developing countries (e.g.
South Africa, other African countries, South American
countries and India). PHRI was launched as a joint Hamil-
ton Health Sciences and McMaster University research
institute in 1999. It is located in the David Braley Cardiac,
Vascular and Stroke Research Institute (DBCVSRI) at
Hamilton General Hospital. The PHRI provides an educa-
tion, training, and mentorship environment for learners
working on cutting-edge projects with world class scien-
tists, with a vision of world class research for new discov-
eries solving global health challenges. PHRI’s research
interests span all frontiers of the globe and include a
broad spectrum of health-related issues. Originally a cardi-
ovascular disease research institute, PHRI’sp r o g r a m sh a v e
expanded to include a broad specrum of medical and soci-
etal conditions in varied populations defined by ethnicity
or geographic region.
The organizational structure of CANNeCTIN includes
Working Groups which are disease/discipline-based (e.g.
interventional cardiology, perioperative medicine, car-
diac surgery) and technological/programmatic in type (e.
g., biostatistics and methodological innovation, pharma-
cogenomics, developing countries, education, knowledge
translation (KT)) collaborative national and international
networks and a coordination centre based within the
PHRI [1]. A detailed description of the programme,
organization, functions and goals is available at http://
www.cannectin.ca.
At the planning stage of the CANNeCTIN program, it
was recognized that biostatisticians play a critical role in
designing health studies (by helping to formulate
research questions and to determine appropriate
research designs, data collection procedures and analytic
strategies) and in conducting analyses of data from stu-
dies to answer scientific questions. The universal short-
age of biostatisticians has been documented in many
countries including the United States [2] and Australia
[3]. In their “Strategy for patient-oriented research”
released in February 2010, CIHR acknowledged that in
Canada “...the clinical research workforce has not grown
since CIHR’s creation in 2000, with obvious shortages of
biostatisticians, health economists, clinical epidemiolo-
gists, social scientists, ...” and further noted that “...most
academic health science centres conducting clinical
research report a critical shortage of biostatisticians and
methodologists“ (http://www.cihr-irsc.gc.ca) [emphasis is
ours]. Canada needs to train and support the careers of
biostatisticians and research methodologists to enhance
its capacity to conduct patient-oriented research with
the potential to improve health and enhance the sustain-
ability of the Canadian healthcare system. A fundamen-
tal goal of CANNeCTIN is to improve this situation.
The objectives of this paper are: 1) to describe the inno-
vative research and training activities of the Biostatistics
and Methodological Innovation Working (BMIW) Group
in building capacity in biostatistics and clinical trial meth-
ods; 2) to disseminate the activities of the BMIW Group
to other interested researchers; and 3) to encourage inter-
ested biostatisticians and methodologically oriented clini-
cal researchers to join the BMIW Group.
The Biostatistics and Methodological Innovation
Working Group
As one of the CANNeCTIN Working Groups, the BMIW
Group was created to bring clinical researchers and bios-
tatisticians together from multiple universities across
Canada to: a) identify and address complex biostatistical
and methodological problems relevant to clinical trials
and epidemiologic studies; b) advise clinical trialists
regarding these issues; and c) build capacity through
practical and interactive training of future biostatisticians
and clinician-methodologists in CVD/DM trials.
Innovations in biostatistical methods have already
played a major role in health research; however, clinical
researchers face increasingly challenging problems
requiring further innovation. Unresolved biostatistical
challenges include: a) optimal ways to analyze pharmaco-
genomic data; b) developing new statistical methods in
the design and analysis of CVD/DM trials; c) addressing
complexities in non-inferiority and adaptive trial designs.
Using simulations and existing datasets from large com-
pleted studies (see PHRI website for a complete listing of
completed and on-going multi-centre studies: http://
www.phri.ca/body.cfm?id=22), the BMIW Group is able
to empirically test their hypotheses on many of the above
biostatistical and methodological issues.
The original core centres in the Group were the Univer-
sity of Waterloo, University of Ottawa, McGill University
and McMaster University with PHRI as the coordinating
centre. Other centres that have joined the Group include
t h eU n i v e r s i t yo fT o r o n t oa n dU n i v e r s i t yo fW e s t e r n
Ontario. Figure 1 shows the key members from each
centre.
Innovations in Biostatistical Research and
Training
Our innovative program of research and training activ-
ities includes: monthly videoconferences on topical bios-
tatistical and methodological issues in CVD/MD clinical
studies; providing presentations on methodological
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and training young statisticians in biostatistics and
methods in CVD/DM trials and organizing annual sym-
posiums on topical methodological issues. These activ-
ities were deliberately chosen to share knowledge,
provoke interactive discussion, stimulate research ideas,
encourage research collaboration and cultivate academic
cross-fertilization among biostatisticians, clinicians and
trainees.
Monthly video-conferences
The BMIW Group holds regular videoconference/webcast
seminars on advanced issues in clinical trials methodology.
The seminars take place every second Friday of the month
between September to June. Participants can join the live
videoconference sites at the Hamilton General Hospital,
McMaster University, University of Waterloo, McGill
University, and the University of Ottawa Heart Institute or
view a live webcast of the presentation through the
Ontario Telemedicine Network (OTN) website (http://
webcast.otn.ca). The webcasts are archived on the OTN
website for two years and then moved to the CANNeC-
TIN website. Individuals interested in taking part in the
videoconferences can email cannectin@phri.ca for infor-
mation about adding their centres to the live videoconfer-
ence, join the videoconference in person at http://www.
cannectin.ca/default.cfm?id=66 or watch a live webcast on
the OTN website. The seminars have been running for
three years and have covered a wide spectrum of issues in
clinical studies (see Table 1). The pdf versions and some
of the video webcasts of presentations are available online
at http://www.cannectin.ca/default.cfm?id=25 and can
form a useful learning resource for individuals both within
t and outside of the network.
Figure 1 Key Members of the CANNeCTIN Biostatistics and Methodological Innovation Group by Centre.
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To facilitate cross-fertilization between statisticians and
clinicians, the BIMW Group regularly engages in inter-
active discussions with clinicians on methodological
issues that arise in CANNeCTIN studies. Clinical inves-
tigators are invited to present to their studies to the
group at our monthly biostatistics videoconferences and
receive input from the group. The group members also
give presentations at the annual CANNeCTIN meeting.
At the CANNeCTIN Junior investigator meeting held in
Winter 2010, the members of the group delivered the
following presentations:
￿ How CANNeCTIN investigators can collaborate
with statisticians at PHRI;
￿ What you need to know about pilot studies: the
what, how and why [4];
￿ Some issues in the design and analysis of RCTs -
covering issues in cluster randomization trials and
time-to-event outcomes; and
￿ Common errors in CIHR RCT grants.
These presentations are available at http://www.can-
nectin.ca/default.cfm?id=116. We plan to continue to fos-
ter these interactions in future meetings and to expand
the coverage to include more topics. The BMIW Group
also participated in the Cutting Edge Symposiums on
Pharmacogenomics that took place in May 2009 and
Perioperative Medicine held in April 2010, in Hamilton
(Ontario, Canada) (http://www.cannectin.ca/body.cfm?
id=68). In these symposiums, we collaborate closely with
our clinician investigators to discuss the biostatistical and
methodological issues arising from different studies. For
example, one of the trials - PADIT (Prevention of
Arrhythmia Device Trial) [ClinicalTrials.gov identifier #:
NCT01002911] involved both the use of both a cross-
over design and cluster-randomization. The trial uses
“site” as a unit of randomization. The primary objective
is to compare conventional pre-operative antibiotics ver-
sus conventional intra-operative plus post-operative anti-
biotics in preventing hospitalization attributed to device
infection in patients undergoing cardiac surgery. This
raised interesting discussions among biostatisticians and
clinicians about the design and analysis of the trial.
The group also takes part in the annual Trout-CAN-
NeCTIN workshop - an intensive, interactive training
program led by Dr David Sackett, which guides young
researchers in the design, implementation, and analysis
of high-quality clinical studies, as well as in effective
grant writing and academic career development. Our
role includes providing biostatistical feedback and sup-
port to the trainees.
Capacity-building through training and
mentorship of young biostatisticians
One of our goals is to build capacity in biostatistics within
Canada through advanced and practical training of graduate
and postgraduate students. This occurs in an interdisciplin-
ary environment, with clinicians and biostatisticians work-
ing together on applied problems. As noted earlier, the
worldwide need for experienced biostatisticians in many
countries is high in all areas of health research [2,3] and
Canada is no exception. Our program is to recruit and train
biostatisticians within Canada with the necessary practical
experience and skills to work with clinical investigators.
The specific objectives of this training and mentorship
Table 1 Coverage of topics and issues at monthly videoconferences for 2008-2010
Topic Issues covered*
Issues in RCTs ￿ Biases resulting from patient withdrawal in RCTs and how to address them;
￿ Design and analysis issues in knowledge translation trials in primary care;
￿ Testing for blinding at the end of an RCT [5];
￿ Prognostic imbalance in RCTs;
￿ Dynamic allocation methods: why the controversy?
￿ Statistical issues in the use of composite outcomes clinical trials.
Issues in cluster RCTs ￿ Clustered measurement in cluster randomized trials;
￿ Imputation strategies for missing binary outcomes in cluster randomized trials.
Non-inferiority designs ￿ What’s wrong with non-inferiority designs?
Pragmatic Trials ￿ A pragmatic-explanatory continuum summary (PRECIS) [6];
Meta-analysis issues ￿ Empirical priors for between-study heterogeneity in meta-analysis;
￿ Precision in meta-analysis;
￿ Indirect comparisons for evaluating healthcare interventions [7].
Other issues ￿ Bias in logistic regression due to omitted covariates;
￿ Statistical genetics and coronary artery disease;
￿ Longitudinal modeling when the response and time-dependent covariates are measured at distinct time-points.
*Pdf Slides and audio versions of the presentations are available at http://www.cannectin.ca/default.cfm?id=25.
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to excellence in statistical collaboration in CVD and DM
clinical research; to enhance communication of statistical
issues to clinician collaborators; to train young statisticians
to acquire biostatistical self-sufficiency and develop skills in
applied statistics in CVD and DM trials; and to enhance a
culture of collaboration among statisticians and clinician
researchers. We introduce our trainees to the rewards and
challenges of health care research, through practical train-
ing obtained by working on real problems that are encoun-
tered in ongoing trials. We provide partial funding for all
CANNeCTIN biostatistics trainees, who have a primary
supervisor at their “home” institution. All supervisors have
to be active members of the BMIW Group. The student
submits a proposal and receives input from all the members
of the group (collective mentoring). By providing hands-on
experience in large clinical studies, our training approach
complements training programs already existing in many
universities and builds biostatistical capacity specific to
CVD and DM trials in Canada.
Table 2 provides a summary of our trainees to date
(11 trainees), their “home” institution, project title and
primary supervisor(s).
Other Activities: Special Invited Sessions at
Scientific Meetings and the Annual Biostatistics
and Methods Symposium
The BMIW Group has organized some special sessions
sponsored by CANNeCTIN at various biostatistical meet-
ings including the Canadian Society for Epidemiology and
Biostatistics annual meeting held in Ottawa (Ontario,
Canada) in, 2009; and the Statistical Society of Canada
annual meeting held in Vancouver (British Columbia,
Canada) in 2009. We are currently organizing another
invited sessions at the annual meetings of the Statistical
Society of Canada (SSC) in Wolfville (Nova Scotia,
Canada) in June 2011 and International Society for Clini-
cal Biostatistics (ISCB) in Ottawa (Ontario, Canada) in
August 2011. These activities have provided good forums
for the group to share their research with national and
international statistical communities
The BMIW group plans to organize annual sympo-
siums on challenging and relevant topics in biostatistics
in RCTs or observational studies that will involve other
experts from Canada and abroad, and be suitable for
publication in peer-reviewed journals. Each symposium
will focus on answering four key questions: 1) what is
the state-of-the-art? ii) what are the outstanding or con-
troversial issues that remain unresolved or need to be
addressed? iii) what guidance can we provide to
researchers on these issues based on the current knowl-
edge?; and iv) what research needs to be done to fully
address the issues?
Topical biostatistical and methodological issues that
have been identified so far include composite outcomes,
stopping rules, surrogate outcomes, non-inferiority
designs, non-compliance, adjustment for baseline imbal-
ance in RCTs, adaptive designs, and large vs. small trials.
The first CANNeCTIN Cutting Edge Symposium on
Advanced Biostatistics and Methodological Issues in
Table 2 Current List of CANNeCTIN Biostatistics Trainees
Institution Trainee Project Supervisor
McMaster
University
Kristian
Thorlund
Methodological improvements in meta-analysis Drs. Lehana Thabane
and PJ Devereaux
Jinhui Ma Issues in the Statistical Analysis and Imputation Strategies for Binary outcome
from Cluster Randomized Trials in Management of Cardiovascular Risk Factors
Dr. Lehana Thabane
Rachel Chu Intraclass correlation in multicentre RCTs and prognostic heterogeneity/imbalance Dr. Lehana Thabane
Hoi Suen Generalised Additive Models for the analysis of health utility data Dr Eleanor
Pullenayegum
University of
Waterloo
Haocheng Li Design of Clinical Trial and Statistical Analysis with Missing Data Dr. Grace Yi
Longyang Wu Design of Clinical Trials with Recurrent Events and Competing Risks Dr. Richard Cook
Audrey
Boruvka
Event history analysis with incomplete data Dr. Richard Cook
Min Chen Empirical Likelihood Methods for Pretest-Posttest Studies Drs Mary Thompson and
Changbao Wu
University of
Ottawa
Robert William
Davies
Statistical Issues Which Pertain to the use of GWAS for the Identification, Characterization
and Quantification of Genetic Effects in Cardiovascular Disease
Dr. George Wells
McGill
University
Maria Esther
Perez Trejo
The problem of extra variation induced by double clustering Dr. Robert Platt
Michael Regier Develop causal methods appropriate for repeatedly measured data Dr. Robert Platt
Menglan Pan Marginal Structural Models, Odds Ratios, and Collapsibility Drs. Robert Platt and Jay
Kaufman
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28-29, 2011, will focus on outcomes in CVD trials - cov-
ering both composite and surrogate outcomes, and
adaptive designs. More details on the symposium can be
found at http://www.cannectin.ca/default.cfm?id=128.
Lessons Learned
Effective use of information technology (IT) to link dif-
ferent centres through videoconferences has been key to
the success of our monthly seminars. Occasionally, we
encounter some technical problems in connecting sites,
but these problems are always resolved without much
difficulty and with some patience. To date, no seminars
have been cancelled because of IT challenges.
Mentoring the next generation of biostatisticians in
cardiovascular trials has been a worthwhile journey so
far. Collectively, we have 11 trainees from four Canadian
universities, supervised or mentored by seven BMIW
Group biostatisticians. We hope that this effort will con-
tinue to expand the training opportunities to more
national and international centres.
Interacting and collaborating with clinicians in addres-
sing CVD/DM problems has been a rewarding experi-
ence for many of us. The CANNeCTIN programme
provides an excellent opportunity to promote academic
dialogue among biostatisticians and clinicians (including
our trainees). By sharing knowledge, provoking interac-
tive discussion, stimulating research ideas, encouraging
collaboration and fostering academic cross-fertilization,
we can make our biostatistical research more relevant
and applicable to important problems in CVD and DM
research.
Some Concluding Remarks
There is a severe shortage of biostatistical expertise in
CVD/DM research. Our efforts to reduce the global bur-
den of these diseases depend on the conduct of large
well-designed trials to advance our understanding of the
key predictors of the disease and the best strategies for
prevention, treatment and management. The BMIW
Group is making substantial contributions towards the
realization of CANNeCTIN’s vision to advance global
health through building the capacity of the Canadian
research community to lead major CVD and DM clinical
trials. The long-term contributions of the BMIW Group
will include the development of new biostatistical meth-
ods and recruitment and training of highly qualified per-
sonnel. These personnel will become leaders in
collaborative health research through contributions to
the design and analysis of CVD/DM trials, and also serve
as committee members and reviewers for granting agen-
cies such as CIHR that support clinical research in
Canada. We believe that with suitable investments, this is
a model that can be useful for building human capacity
in other areas of clinical research experiencing similar
shortage of biostatistical expertise.
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